Sang M. Lee

Sang M. Lee

Auto-generated profile, based on publicly available information

Sang M. Lee

Department of Biomedical Engineering, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
XWXu Wang
Xu Wang
SLShuai Liu
Shuai Liu
YSYehui Sun
Yehui Sun
XYXueliang Yu
Xueliang Yu
SLSang M. Lee
Sang M. Lee
DSDaniel Siegwart
Daniel Siegwart

14 June 2024 in Science
Verified
Journal Article
Closed access
YSYehui Sun
Yehui Sun
SCSumanta Chatterjee
Sumanta Chatterjee
XLXizhen Lian
Xizhen Lian
ZTZachary Traylor
Zachary Traylor
SSSandhya R. Sattiraju
Sandhya R. Sattiraju
DSDaniel Siegwart
Daniel Siegwart
In vivo genome correction holds promise for generating durable disease cures; yet, effective stem cell editing remains challenging. In this work, we demonstrate that optimized lung-targeting lipid nanoparticles (LNPs) enable high levels of genome editing in stem cells, yielding durable responses. Intravenously administered gene-editing LNPs in activatable tdTomato mice achieved >70% lung stem cell editing, sustaining tdTomato expression in >80% of lung epithelial cells for 660 days. Addressing cystic fibrosis (CF), NG-ABE8e messenger RNA (mRNA)–sgR553X LNPs mediated >95% cystic fibrosis transmembrane conductance regulator (CFTR) DNA correction, restored CFTR function in primary patient-derived bronchial epithelial cells equivalent to Trikafta for F508del, corrected intestinal organoids and corrected R553X nonsense mutations in 50% of lung stem cells in CF mice. These findings introduce LNP-enabled tissue stem cell editing for disease-modifying genome correction.

26 September 2022 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
LJLindsay T. Johnson
Lindsay T. Johnson
DZDi Zhang
Di Zhang
KZKejin Zhou
Kejin Zhou
SLSang M. Lee
Sang M. Lee
SLShuai Liu
Shuai Liu
DSDaniel Siegwart
Daniel Siegwart

2 June 2025 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MKMinjeong Kim
Minjeong Kim
ESEunice S. Song
Eunice S. Song
JCJoseph C. Chen
Joseph C. Chen
SCSumanta Chatterjee
Sumanta Chatterjee
YSYehui Sun
Yehui Sun
DSDaniel Siegwart
Daniel Siegwart

11 September 2025 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
YKYujin Kim
Yujin Kim
SCSumanta Chatterjee
Sumanta Chatterjee
ARAva L. Robertson
Ava L. Robertson
EGErick D. Guerrero
Erick D. Guerrero
AVAmogh Vaidya
Amogh Vaidya
DSDaniel Siegwart
Daniel Siegwart

18 December 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
QCQiang Cheng
Qiang Cheng
LFLukas Farbiak
Lukas Farbiak
AVAmogh Vaidya
Amogh Vaidya
EGErick Guerrero
Erick Guerrero
ELEunice E. Lee
Eunice E. Lee
DSDaniel Siegwart
Daniel Siegwart
Genetic medicines have the potential to treat various diseases; however, certain ailments including inflammatory diseases and cancer would benefit from control over extracellular localization of therapeutic proteins. A critical gap therefore remains the need to develop and incorporate methodologies that allow for posttranslational control over expression dynamics, localization, and stability of nucleic acid–generated protein therapeutics. To address this, we explored how the body’s endogenous machinery controls protein localization through signal peptides (SPs), including how these motifs could be incorporated modularly into therapeutics. SPs serve as a virtual zip code for mRNA transcripts that direct the cell where to send completed proteins within the cell and the body. Utilizing this signaling biology, we incorporated secretory SP sequences upstream of mRNA transcripts coding for reporter, natural, and therapeutic proteins to induce secretion of the proteins into systemic circulation. SP sequences generated secretion of various engineered proteins into the bloodstream following intravenous, intramuscular, and subcutaneous SP mRNA delivery by lipid, polymer, and ionizable phospholipid delivery carriers. SP-engineered etanercept/TNF-α inhibitor proteins demonstrated therapeutic efficacy in an imiquimod-induced psoriasis model by reducing hyperkeratosis and inflammation. An SP-engineered anti-PD-L1 construct mediated mRNA encoded proteins with longer serum half-lives that reduced tumor burden and extended survival in MC38 and B16F10 cancer models. The modular nature of SP platform should enable intracellular and extracellular localization control of various functional proteins for diverse therapeutic applications.